Bryan Zhu specializes in capital markets, listed company compliance and transactions, with emphasis on advising sponsors, underwriters, and issuers on the Hong Kong IPOs. Bryan has significant experience navigating IPO vetting processes, post-listing compliance, and follow-on capital markets transactions for Chinese and international companies across industries including healthcare, pharmaceuticals, financial services, technology, and manufacturing.
Prior to joining O’Melveny, Bryan worked in the capital markets teams of several leading international law firms, where he advised sponsors and issuers on numerous listed and ongoing Hong Kong IPOs, as well as on post-listing compliance and debt capital markets transactions.
Hong Kong IPOs – Company Side:
- Sinotau in its proposed Hong Kong IPO (ongoing)
- Huahui Health in its proposed Hong Kong IPO (ongoing)
- Zephyrm Biotech in its proposed Hong Kong IPO (ongoing)
- S.F. Holding Co., Ltd. (6936.HK) in its approximately HK$5.8 billion IPO and listing on the Hong Kong Stock Exchange*
- JL MAG RARE-EARTH CO., LTD. (6680.HK) in its approximately HK$4 billion IPO and listing on the Hong Kong Stock Exchange*
- Mediwelcome Healthcare Management & Technology Inc. (2159.HK) in its approximately HK$160 million IPO and listing on the Hong Kong Stock Exchange*
- Jiangsu Innovative Ecological New Materials Limited (2116.HK)* in its approximately HK$150 million IPO and listing on the Hong Kong Stock Exchange*
- Inner Mongolia Energy Engineering Co., Ltd. (1649.HK) in its approximately HK$1.1 billion IPO and listing on the Hong Kong Stock Exchange*
Hong Kong IPOs – Sponsor Side:
- CICC and CMS as joint sponsors in the approximately HK$600 million IPO and listing of QingSong Health Corporation (2661.HK) on the Hong Kong Stock Exchange*
- CITICS and CICC as joint sponsors in the approximately HK$680 million IPO and listing of Guangzhou Innogen Pharmaceutical Group Co., Ltd. (2591.HK) on the Hong Kong Stock Exchange*
- CICC as the sole sponsor in the approximately HK$460 million IPO and listing of Sunho Biologics, Inc. (2898.HK) on the Hong Kong Stock Exchange*
- CITICS as the sole sponsor in the approximately HK$1.04 billion IPO and listing of XtalPi Inc. (2228.HK) on the Hong Kong Stock Exchange*
- CICC and CITICS as joint sponsors in the A+H listing of JA Solar Technology Co., Ltd. on the Hong Kong Stock Exchange*
- CITICS and Fosun International as joint sponsors in the proposed Hong Kong IPO of Boche Holding Limited (Cayman)*
- Huatai International as the sole sponsor in the approximately HK$460 million IPO and listing of AuGroup (SHENZHEN) Cross-Border Business Co., Ltd. (2519.HK) on the Hong Kong Stock Exchange*
- CICC as the sole sponsor in the approximately HK$310 million IPO and listing of Xiamen Yan Palace Bird's Nest Industry Co., Ltd. (1497.HK) on the Hong Kong Stock Exchange*
- CICC as the sole sponsor in the approximately HK$640 million IPO and listing of Xikang Cloud Hospital Holdings Inc. (9686.HK) on the Hong Kong Stock Exchange*
- CICC and GS as joint sponsors in the proposed Hong Kong IPO of Neusoft Medical*
- CICC and China Securities as joint sponsors in the approximately HK$410 million IPO and listing of 3D Medicines Inc. (1244.HK) on the Hong Kong Stock Exchange*
- CMBC International as the sole sponsor in the approximately HK$1.09 billion IPO and listing of UJU HOLDINGLIMITED (1948.HK) on the Hong Kong Stock Exchange*
- Shenwan Hongyuan as the sole sponsor in the approximately HK$130 million IPO and listing of Desun Real Estate Investment Services Group Co., Ltd. (2270.HK) on the Hong Kong Stock Exchange*
- China Securities as the sole sponsor in the HK$60 million IPO and listing of Doumob (1917.HK) on the Hong Kong Stock Exchange*
- CICC, MS, BofA, GS, JPM as joint sponsors in the US$7.43 billion IPO and listing of Postal Savings Bank of China Co., Ltd. (1658.HK) on the Hong Kong Stock Exchange*
Other Capital Markets Experience
- China Huaneng Group (Hong Kong) Treasury Management Holding Limited (5089.HK) in the offering of US$500 million subordinated guaranteed perpetual securities*
- Newborn Town Inc. (9911.HK) in its approximately HK$350 million placing of new H shares under general mandate*
- Newborn Town Inc. (9911.HK) in an equity acquisition transaction*
- SINOPEC SEG (2386.HK) in its major transactions*
- Qinghuangdao Port (3369.HK) in its major transactions*
- Fusi Capital in its equity investment in an education company*
- DSHL, Inc. in its Series B financing*
- BAIC BJEV in its equity investment in a battery manufacturing company*
Compliance Matters:
- Advised the following Hong Kong-listed companies on compliance matters, including: INT Medical Instruments (1501.HK), Fosun Pharma (2196.HK)*, Bank of Communications Co., Ltd. (3328.HK)*, China Merchants Bank Co., Ltd (3968.HK)*, Newborn Town Inc. (9911.HK)*, SINOPEC Engineering (Group) Co., Ltd. (2386.HK)*, Qinhuangdao Port Co., Ltd. (3369.HK)*, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK)*, and E-Commodities Holdings Limited (fka. Winsway Enterprises Holding Limited) (1733.HK)*
* Work performed prior to joining O’Melveny
Languages
- English
- Mandarin Chinese
Admissions
- New York
Education
- Boston University School of Law, LL.M.
- China University of Political Science and Law, LL.B.
Professional Activities
Bar Exam
- Passed Chinese Bar Exam